Theodoros Karantanos1, Christopher P Evans2, Bertrand Tombal3, Timothy C Thompson4, Rodolfo Montironi5, William B Isaacs6. 1. Department of Genitourinary Medical Oncology-Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: theodoroskarantanosmd@gmail.com. 2. Department of Urology, UC Davis Comprehensive Cancer Center, Sacramento, CA, USA. 3. Cliniques universitaires Saint Luc, Université catholique de Louvain, Brussels, Belgium. 4. Department of Genitourinary Medical Oncology-Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, Ancona, Italy. 6. Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Abstract
CONTEXT: Various molecular mechanisms play a role in the development of resistance to androgen deprivation therapy in castration-resistant prostate cancer (CRPC). OBJECTIVE: To understand the mechanisms and biological pathways associated with the progression of prostate cancer (PCa) under systemic androgen depletion or administration of the novel antiandrogens abiraterone, enzalutamide, and ARN-509. This review also examines the introduction of novel combinational approaches for patients with CRPC. EVIDENCE ACQUISITION: PubMed was the data source. Keywords for the search were castrate resistant prostate cancer, abiraterone, enzalutamide resistance mechanisms, resistance to androgen deprivation, AR mutations, amplifications, splice variants, and AR alterations. Papers published before 1990 were excluded from the review, and only English-language papers were included. EVIDENCE SYNTHESIS: This review summarizes the current literature regarding the mechanisms implicated in the development of CRPC and the acquisition of resistance to novel antiandrogen axis agents. The review focuses on androgen biosynthesis in the tumor microenvironment, androgen receptor (AR) alterations and post-transcriptional modifications, the role of glucocorticoid receptor, and alternative oncogenic signaling that is derepressed on maximum AR inhibition and thus promotes cancer survival and progression. CONCLUSIONS: The mechanisms implicated in the development of resistance to AR inhibition in PCa are multiple and complex, involving virtually all classes of genomic alteration and leading to a host of selective/adaptive responses. Combinational therapeutic approaches targeting both AR signaling and alternative oncogenic pathways may be reasonable for patients with CRPC. PATIENT SUMMARY: We looked for mechanisms related to the progression of PCa in patients undergoing hormonal therapy and treatment with novel drugs targeting the AR. Based on recent data, combining maximal AR inhibition with novel agents targeting other tumor-compensatory, non-AR-related pathways may improve the survival and quality of life of patients with castration-resistant PCa.
CONTEXT: Various molecular mechanisms play a role in the development of resistance to androgen deprivation therapy in castration-resistant prostate cancer (CRPC). OBJECTIVE: To understand the mechanisms and biological pathways associated with the progression of prostate cancer (PCa) under systemic androgen depletion or administration of the novel antiandrogens abiraterone, enzalutamide, and ARN-509. This review also examines the introduction of novel combinational approaches for patients with CRPC. EVIDENCE ACQUISITION: PubMed was the data source. Keywords for the search were castrate resistant prostate cancer, abiraterone, enzalutamide resistance mechanisms, resistance to androgen deprivation, AR mutations, amplifications, splice variants, and AR alterations. Papers published before 1990 were excluded from the review, and only English-language papers were included. EVIDENCE SYNTHESIS: This review summarizes the current literature regarding the mechanisms implicated in the development of CRPC and the acquisition of resistance to novel antiandrogen axis agents. The review focuses on androgen biosynthesis in the tumor microenvironment, androgen receptor (AR) alterations and post-transcriptional modifications, the role of glucocorticoid receptor, and alternative oncogenic signaling that is derepressed on maximum AR inhibition and thus promotes cancer survival and progression. CONCLUSIONS: The mechanisms implicated in the development of resistance to AR inhibition in PCa are multiple and complex, involving virtually all classes of genomic alteration and leading to a host of selective/adaptive responses. Combinational therapeutic approaches targeting both AR signaling and alternative oncogenic pathways may be reasonable for patients with CRPC. PATIENT SUMMARY: We looked for mechanisms related to the progression of PCa in patients undergoing hormonal therapy and treatment with novel drugs targeting the AR. Based on recent data, combining maximal AR inhibition with novel agents targeting other tumor-compensatory, non-AR-related pathways may improve the survival and quality of life of patients with castration-resistant PCa.
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Mari Nakabayashi; Lilian Werner; Kevin D Courtney; Geoffrey Buckle; William K Oh; Glen J Bubley; Julia H Hayes; Douglas Weckstein; Aymen Elfiky; Danny M Sims; Philip W Kantoff; Mary-Ellen Taplin Journal: BJU Int Date: 2012-08-29 Impact factor: 5.588
Authors: Yingming Li; Siu Chiu Chan; Lucas J Brand; Tae Hyun Hwang; Kevin A T Silverstein; Scott M Dehm Journal: Cancer Res Date: 2012-11-01 Impact factor: 12.701
Authors: Siting Feng; Qizhu Tang; Meng Sun; Jae Yeon Chun; Christopher P Evans; Allen C Gao Journal: Mol Cancer Ther Date: 2009-02-24 Impact factor: 6.261
Authors: Manav Korpal; Joshua M Korn; Xueliang Gao; Daniel P Rakiec; David A Ruddy; Shivang Doshi; Jing Yuan; Steve G Kovats; Sunkyu Kim; Vesselina G Cooke; John E Monahan; Frank Stegmeier; Thomas M Roberts; William R Sellers; Wenlai Zhou; Ping Zhu Journal: Cancer Discov Date: 2013-07-10 Impact factor: 39.397
Authors: Varadha Balaji Venkadakrishnan; Adam D DePriest; Sangeeta Kumari; Dhirodatta Senapati; Salma Ben-Salem; Yixue Su; Giridhar Mudduluru; Qiang Hu; Eduardo Cortes; Elena Pop; James L Mohler; Gissou Azabdaftari; Kristopher Attwood; Rajal B Shah; Christina Jamieson; Scott M Dehm; Cristina Magi-Galluzzi; Eric Klein; Nima Sharifi; Song Liu; Hannelore V Heemers Journal: Oncogene Date: 2019-02-11 Impact factor: 9.867
Authors: Jamie M Sperger; Lindsay N Strotman; Allison Welsh; Benjamin P Casavant; Zachery Chalmers; Sacha Horn; Erika Heninger; Stephanie M Thiede; Jacob Tokar; Benjamin K Gibbs; David J Guckenberger; Lakeesha Carmichael; Scott M Dehm; Philip J Stephens; David J Beebe; Scott M Berry; Joshua M Lang Journal: Clin Cancer Res Date: 2016-07-11 Impact factor: 12.531